Effectiveness of Double-Dose Dolutegravir in People Receiving Rifampin-based Tuberculosis Treatment: An Observational, Cohort Study of People With HIV From 6 Countries
Clinical Infectious Diseases · 2025
DOI: 10.1093/cid/ciae269 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von N Sarita Shah und 20 weiteren Autor:innen. Beteiligte Einrichtung: Emory Rollins School of Public Health, Emory University, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, HIV Infections, Tuberculosis, Rifampin. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, Emory Georgia TB Research Advancement Center, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Background
Tenofovir-lamivudine-dolutegravir (TLD) is the preferred first-line antiretroviral therapy (ART) regimen. An additional 50-mg dose of dolutegravir (TLD+50) is required with rifampin-containing tuberculosis (TB) co-treatment. There are limited data on the effectiveness of TLD+50 in individuals with TB/human immunodeficiency virus (HIV).
Methods
We performed a prospective, observational cohort study at 12 sites in Haiti, Kenya, Malawi, South Africa, Uganda, and Zimbabwe. Participants starting TLD and rifampin-containing TB treatment were eligible. The primary outcome was HIV-1 RNA ≤1000 copies/mL at end of TB treatment.
Results
We enrolled 91 participants with TB/HIV: 75 (82%) ART-naive participants starting TLD after a median 15 days on TB treatment, 10 (11%) ART-naive participants starting TLD and TB treatment, 5 (5%) starting TB treatment after a median 3.3 years on TLD, and 1 (1%) starting TB treatment and TLD after changing from efavirenz-lamivudine-tenofovir. Median age was 37 years, 35% were female, the median CD4 count was 120 cells/mm3 (interquartile range, 50–295), and 87% had HIV-1 RNA >1000 copies/mL. Among 89 surviving participants, 80 were followed to TB treatment completion, including 7 who had no HIV-1 RNA result due to missed visits. The primary virologic outcome was assessed in 73 participants, 69 of whom (95%; 95% confidence interval, 89%–100%) had HIV-1 RNA ≤1000 copies/mL. No dolutegravir resistance mutations were detected among 4 participants with HIV-1 RNA >1000 copies/mL.
Conclusions
In programmatic settings, concurrent rifampin-containing TB treatment and TLD+50 was feasible, well tolerated, and achieved high viral suppression rates in a cohort of predominantly ART-naive people with TB/HIV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Emory Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
- Joint Clinical Research Centre, Kampala, Uganda.
- Center for Biostatistics in AIDS Research in the Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
- Lancet Laboratories and BARC-SA, Johannesburg, South Africa.
- University of North Carolina at Chapel Hill, School of Medicine, Department of Medicine, Chapel Hill, North Carolina, USA.
- Department of Research, Walter Reed Project-Kericho, Kenya.
ORCID-Profile: N Sarita Shah
Förderung
- NIAID NIH HHS
- Emory Georgia TB Research Advancement Center
- National Institute of Allergy and Infectious Diseases
- NIH HHS
- ACTG
Zitieren
APA
Shah, N. S., Kityo, C., Hughes, M. D., McCarthy, C., Wallis, C. L., Hosseinipour, M. C., Langat, D., Nyirenda, M., Rassool, M., Dawson, R., Joseph, Y., Some, F., Mngqibisa, R., Mukwekwerere, P. G., Woolley, E., Godfrey, C., Manabe, Y. C., Mellors, J. W., Flexner, C., …, & ACTG A5381/Hakim Study Team (2025). Effectiveness of Double-Dose Dolutegravir in People Receiving Rifampin-based Tuberculosis Treatment: An Observational, Cohort Study of People With HIV From 6 Countries. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae269
Vancouver
Shah NS, Kityo C, Hughes MD, McCarthy C, Wallis CL, Hosseinipour MC, et al. Effectiveness of Double-Dose Dolutegravir in People Receiving Rifampin-based Tuberculosis Treatment: An Observational, Cohort Study of People With HIV From 6 Countries. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciae269
BibTeX
@article{Shah2025,
author = {Shah, N Sarita and Kityo, Cissy and Hughes, Michael D and McCarthy, Caitlyn and Wallis, Carole L and Hosseinipour, Mina C and Langat, Deborah and Nyirenda, Mulinda and Rassool, Mohammed and Dawson, Rodney and Joseph, Yvetot and Some, Fatma and Mngqibisa, Rosie and Mukwekwerere, Pamela Grace and Woolley, Elizabeth and Godfrey, Catherine and Manabe, Yukari C and Mellors, John W and Flexner, Charles and Maartens, Gary and ACTG A5381/Hakim Study Team, ACTG A5381/Hakim Study Team},
title = {Effectiveness of Double-Dose Dolutegravir in People Receiving Rifampin-based Tuberculosis Treatment: An Observational, Cohort Study of People With HIV From 6 Countries},
journal = {Clinical Infectious Diseases},
year = {2025},
doi = {10.1093/cid/ciae269}
}
EUVIMED